Literature DB >> 27601186

Mismatch repair gene mutation spectrum in the Swedish Lynch syndrome population.

Kristina Lagerstedt-Robinson1, Anna Rohlin2, Christos Aravidis3, Beatrice Melin4, Margareta Nordling2, Marie Stenmark-Askmalm5, Annika Lindblom1, Mef Nilbert6.   

Abstract

Lynch syndrome caused by constitutional mismatch‑repair defects is one of the most common hereditary cancer syndromes with a high risk for colorectal, endometrial, ovarian and urothelial cancer. Lynch syndrome is caused by mutations in the mismatch repair (MMR) genes i.e., MLH1, MSH2, MSH6 and PMS2. After 20 years of genetic counseling and genetic testing for Lynch syndrome, we have compiled the mutation spectrum in Sweden with the aim to provide a population-based perspective on the contribution from the different MMR genes, the various types of mutations and the influence from founder mutations. Mutation data were collected on a national basis from all laboratories involved in genetic testing. Mutation analyses were performed using mainly Sanger sequencing and multiplex ligation-dependent probe amplification. A total of 201 unique disease-predisposing MMR gene mutations were identified in 369 Lynch syndrome families. These mutations affected MLH1 in 40%, MSH2 in 36%, MSH6 in 18% and PMS2 in 6% of the families. A large variety of mutations were identified with splice site mutations being the most common mutation type in MLH1 and frameshift mutations predominating in MSH2 and MSH6. Large deletions of one or several exons accounted for 21% of the mutations in MLH1 and MSH2 and 22% in PMS2, but were rare (4%) in MSH6. In 66% of the Lynch syndrome families the variants identified were private and the effect from founder mutations was limited and predominantly related to a Finnish founder mutation that accounted for 15% of the families with mutations in MLH1. In conclusion, the Swedish Lynch syndrome mutation spectrum is diverse with private MMR gene mutations in two-thirds of the families, has a significant contribution from internationally recognized mutations and a limited effect from founder mutations.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27601186     DOI: 10.3892/or.2016.5060

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  18 in total

1.  Expanding clinical phenotype in CACNA1C related disorders: From neonatal onset severe epileptic encephalopathy to late-onset epilepsy.

Authors:  Xiuhua Bozarth; Jennifer N Dines; Qian Cong; Ghayda M Mirzaa; Kimberly Foss; J Lawrence Merritt; Jenny Thies; Heather C Mefford; Edward Novotny
Journal:  Am J Med Genet A       Date:  2018-12-04       Impact factor: 2.802

2.  Correlation of MLH1 polymorphisms, survival statistics, in silico assessment and gene downregulation with clinical outcomes among breast cancer cases.

Authors:  Saima Shakil Malik; Ayisha Zia; Sumaira Mubarik; Nosheen Masood; Sajid Rashid; Alice Sherrard; Muhammad Bilal Khan; Muhammad Tahir Khadim
Journal:  Mol Biol Rep       Date:  2019-11-08       Impact factor: 2.316

Review 3.  Genetic predisposition to colorectal cancer: syndromes, genes, classification of genetic variants and implications for precision medicine.

Authors:  Laura Valle; Eduardo Vilar; Sean V Tavtigian; Elena M Stoffel
Journal:  J Pathol       Date:  2019-02-20       Impact factor: 7.996

4.  MutL homolog 1 germline mutation c.(453+1_454-1)_(545+1_546-1)del identified in lynch syndrome: A case report and review of literature.

Authors:  Xi-Wen Zhang; Zan-Hui Jia; Li-Ping Zhao; Yi-Shi Wu; Man-Hua Cui; Yan Jia; Tian-Min Xu
Journal:  World J Clin Cases       Date:  2022-07-16       Impact factor: 1.534

5.  Familial Associations of Colorectal Cancer with Other Cancers.

Authors:  Hongyao Yu; Akseli Hemminki; Kristina Sundquist; Kari Hemminki
Journal:  Sci Rep       Date:  2017-07-12       Impact factor: 4.379

6.  Genetic anticipation in Swedish Lynch syndrome families.

Authors:  Jenny von Salomé; Philip S Boonstra; Masoud Karimi; Gustav Silander; Marie Stenmark-Askmalm; Samuel Gebre-Medhin; Christos Aravidis; Mef Nilbert; Annika Lindblom; Kristina Lagerstedt-Robinson
Journal:  PLoS Genet       Date:  2017-10-31       Impact factor: 5.917

7.  A survey of the clinicopathological and molecular characteristics of patients with suspected Lynch syndrome in Latin America.

Authors:  Benedito Mauro Rossi; Edenir Inêz Palmero; Francisco López-Kostner; Carlos Sarroca; Carlos Alberto Vaccaro; Florencia Spirandelli; Patricia Ashton-Prolla; Yenni Rodriguez; Henrique de Campos Reis Galvão; Rui Manuel Reis; André Escremim de Paula; Luis Gustavo Capochin Romagnolo; Karin Alvarez; Adriana Della Valle; Florencia Neffa; Pablo German Kalfayan; Enrique Spirandelli; Sergio Chialina; Melva Gutiérrez Angulo; Maria Del Carmen Castro-Mujica; Julio Sanchez de Monte; Richard Quispe; Sabrina Daniela da Silva; Norma Teresa Rossi; Claudia Barletta-Carrillo; Susana Revollo; Ximena Taborga; L Lena Morillas; Hélène Tubeuf; Erika Maria Monteiro-Santos; Tamara Alejandra Piñero; Constantino Dominguez-Barrera; Patrik Wernhoff; Alexandra Martins; Eivind Hovig; Pål Møller; Mev Dominguez-Valentin
Journal:  BMC Cancer       Date:  2017-09-05       Impact factor: 4.430

8.  Haplotype analysis suggest that the MLH1 c.2059C > T mutation is a Swedish founder mutation.

Authors:  Jenny von Salomé; Tao Liu; Markku Keihäs; Moni Morak; Elke Holinski-Feder; Ian R Berry; Jukka S Moilanen; Stéphanie Baert-Desurmont; Annika Lindblom; Kristina Lagerstedt-Robinson
Journal:  Fam Cancer       Date:  2018-10       Impact factor: 2.375

9.  A retrospective study of extracolonic, non-endometrial cancer in Swedish Lynch syndrome families.

Authors:  Masoud Karimi; Jenny von Salomé; Christos Aravidis; Gustav Silander; Marie Stenmark Askmalm; Isabelle Henriksson; Samuel Gebre-Medhin; Jan-Erik Frödin; Erik Björck; Kristina Lagerstedt-Robinson; Annika Lindblom; Emma Tham
Journal:  Hered Cancer Clin Pract       Date:  2018-10-23       Impact factor: 2.857

10.  Familial risks of second primary cancers and mortality in ovarian cancer patients.

Authors:  Guoqiao Zheng; Subhayan Chattopadhyay; Asta Försti; Kristina Sundquist; Kari Hemminki
Journal:  Clin Epidemiol       Date:  2018-10-11       Impact factor: 4.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.